<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">9151898</PMID>
        <DateCompleted>
            <Year>1997</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-1007</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>185</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>May</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of experimental medicine</Title>
                <ISOAbbreviation>J. Exp. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1605-17</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Epstein-Barr virus (EBV), a human gamma-herpesvirus, can establish both nonproductive (latent) and productive (lytic) infections. Although the CD8+ cytotoxic T lymphocyte (CTL) response to latently infected cells is well characterized, very little is known about T cell controls over lytic infection; this imbalance in our understanding belies the importance of virus-replicative lesions in several aspects of EBV disease pathogenesis. The present work shows that the primary CD8+ CTL response to EBV in infectious mononucleosis patients contains multiple lytic antigen-specific reactivities at levels at least as high as those seen against latent antigens; similar reactivities are also detectable in CTL memory. Clonal analysis revealed individual responses to the two immediate early proteins BZLF1 and BRLF1, and to three (BMLF1, BMRF1, and BALF2) of the six early proteins tested. In several cases, the peptide epitope and HLA-restricting determinant recognized by these CTLs has been defined, one unusual feature being the number of responses restricted through HLA-C alleles. The work strongly suggests that EBV-replicative lesions are subject to direct CTL control in vivo and that immediate early and early proteins are frequently the immunodominant targets. This contrasts with findings in alpha- and beta-herpesvirus systems (herpes simplex, cytomegalovirus) where viral interference with the antigen-processing pathway during lytic infection renders immediate early and early proteins much less immunogenic. The unique capacity of gamma-herpesvirus to amplify the viral load in vivo through a latent growth-transforming infection may have rendered these agents less dependent upon viral replication as a means of successfully colonizing their hosts.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Steven</LastName>
                    <ForeName>N M</ForeName>
                    <Initials>NM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research Campaign Institute for Cancer Studies, University of Birmingham, U.K.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Annels</LastName>
                    <ForeName>N E</ForeName>
                    <Initials>NE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leese</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurilla</LastName>
                    <ForeName>M G</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rickinson</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Exp Med</MedlineTA>
            <NlmUniqueID>2985109R</NlmUniqueID>
            <ISSNLinking>0022-1007</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C063676">BZLF1 protein, Herpesvirus 4, Human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C083204">Epstein-Barr virus early antigen diffuse component</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017874">Immediate-Early Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12005-9</RefSource>
                <PMID Version="1">8265661</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1994 May 20;77(4):525-35</RefSource>
                <PMID Version="1">8187174</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gen Virol. 1994 Sep;75 ( Pt 9):2489-93</RefSource>
                <PMID Version="1">7521394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1994 Nov;68(11):7374-85</RefSource>
                <PMID Version="1">7933121</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1995 Feb 1;85(3):744-50</RefSource>
                <PMID Version="1">7530505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1995 Feb 24;80(4):593-601</RefSource>
                <PMID Version="1">7532548</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1995 Jun 1;181(6):2221-8</RefSource>
                <PMID Version="1">7539044</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1995 Jun 1;375(6530):411-5</RefSource>
                <PMID Version="1">7760935</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1995 Jun 1;375(6530):415-8</RefSource>
                <PMID Version="1">7760936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1995 Aug;69(8):4830-41</RefSource>
                <PMID Version="1">7609050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1995 Aug;69(8):4872-9</RefSource>
                <PMID Version="1">7609055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gen Virol. 1995 Sep;76 ( Pt 9):2393-8</RefSource>
                <PMID Version="1">7561783</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 1995 Dec;50(12):1234-9</RefSource>
                <PMID Version="1">8553293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1996 Mar 8;84(5):769-79</RefSource>
                <PMID Version="1">8625414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virology. 1996 May 15;219(2):489-92</RefSource>
                <PMID Version="1">8638417</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 1996 Aug;2(8):906-11</RefSource>
                <PMID Version="1">8705861</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1996 Oct 24;383(6602):720-2</RefSource>
                <PMID Version="1">8878482</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1996 Nov 1;184(5):1791-800</RefSource>
                <PMID Version="1">8920867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1996 Nov 1;184(5):1801-13</RefSource>
                <PMID Version="1">8920868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1996 Sep 1;184(3):971-80</RefSource>
                <PMID Version="1">9064357</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Immunol. 1997;15:405-31</RefSource>
                <PMID Version="1">9143694</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunology. 1992 May;76(1):174-5</RefSource>
                <PMID Version="1">1378424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1985 Jan;53(1):107-13</RefSource>
                <PMID Version="1">2981328</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 1985 Jan 15;35(1):35-42</RefSource>
                <PMID Version="1">2981780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 1985 Jan 15;35(1):43-9</RefSource>
                <PMID Version="1">2981781</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1985 Dec 19;313(25):1564-71</RefSource>
                <PMID Version="1">2999595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1985 Dec 21-28;2(8469-70):1390-3</RefSource>
                <PMID Version="1">2867394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1986 Oct;60(1):140-8</RefSource>
                <PMID Version="1">3018281</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1987 Oct;61(10):3120-32</RefSource>
                <PMID Version="1">3041034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virology. 1987 Sep;160(1):151-61</RefSource>
                <PMID Version="1">2820125</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1988 Sep 1;168(3):919-31</RefSource>
                <PMID Version="1">2844952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1988 Oct 1;168(4):1211-24</RefSource>
                <PMID Version="1">2459295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1989 Jan;63(1):445-9</RefSource>
                <PMID Version="1">2462063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 1989 Jan 15;43(1):67-71</RefSource>
                <PMID Version="1">2536009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1989 Sep;63(9):3878-83</RefSource>
                <PMID Version="1">2548003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1989 Nov;63(11):4609-15</RefSource>
                <PMID Version="1">2552144</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1990 Jan;64(1):313-21</RefSource>
                <PMID Version="1">2152819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1990 Jan 1;171(1):345-9</RefSource>
                <PMID Version="1">1688611</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1990 Aug;64(8):3753-9</RefSource>
                <PMID Version="1">2164595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1991 Apr 15;146(8):2795-804</RefSource>
                <PMID Version="1">1707922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1991 Jun;65(6):2868-74</RefSource>
                <PMID Version="1">1851858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virology. 1991 Sep;184(1):330-40</RefSource>
                <PMID Version="1">1651595</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1992 Mar;66(3):1622-34</RefSource>
                <PMID Version="1">1310769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1992 Mar 6;255(5049):1261-3</RefSource>
                <PMID Version="1">1546328</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1992 Jul 1;176(1):157-68</RefSource>
                <PMID Version="1">1319456</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1992 Jul 1;176(1):169-76</RefSource>
                <PMID Version="1">1377222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1992 Oct 1;149(7):2406-14</RefSource>
                <PMID Version="1">1326579</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1992 Oct 1;176(4):937-50</RefSource>
                <PMID Version="1">1383381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1992 Dec;66(12):7461-8</RefSource>
                <PMID Version="1">1331531</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1984 May 10;310(19):1225-30</RefSource>
                <PMID Version="1">6323983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1993 Jun;67(6):3461-9</RefSource>
                <PMID Version="1">8388509</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1993 Jun 15;81(12):3350-6</RefSource>
                <PMID Version="1">8389615</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006566" MajorTopicYN="N">Herpesviridae Infections</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017874" MajorTopicYN="N">Immediate-Early Proteins</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007244" MajorTopicYN="N">Infectious Mononucleosis</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9151898</ArticleId>
            <ArticleId IdType="pmc">PMC2196300</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
